This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/kegg-drug/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/chemspider/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/kegg-compound/
n5http://linked.opendata.cz/resource/drugbank/drug/DB05262/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05262
rdf:type
n6:Drug
n6:description
Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
n6:generalReferences
# Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I: Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5. Epub 2005 Aug 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16135657 # Baldus S, Koster R, Chumley P, Heitzer T, Rudolph V, Ostad MA, Warnholtz A, Staude HJ, Thuneke F, Koss K, Berger J, Meinertz T, Freeman BA, Munzel T: Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med. 2005 Nov 1;39(9):1184-90. Epub 2005 Aug 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16214034 # Reyes AJ, Leary WP: Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story? Cardiovasc Drugs Ther. 2005 Oct;19(5):311-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16382292
n6:group
investigational
n6:halfLife
23.3 +/- 6.0 hours
n6:indication
Intended for the treatment of congestive heart failure and hyperuricemia.
owl:sameAs
n14:DB05262
dcterms:title
Oxypurinol
adms:identifier
n4:D02365 n5:4644 n7:DB05262 n8:C07599 n9:28315 n10:4483 n11:7849424
n6:mechanismOfAction
Oxypurinol inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xanthine oxidase through negative feedback results in a decrease in the concentrations of uric acid in the blood and urine. Oxypurinol also facilitates the incorporation of hypoxanthine and xanthine into DNA and RNA, resulting in further reductions of serum uric acid concentrations.
n6:synonym
1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione Oxipurinol 6-hydroxy allopurinol Oxipurinolum Alloxanthin Oxoallopurinol metabolite of allopurinol Oxyprim 1H-Pyrazolo[3,4-d]pyrimidine-4,6-diol Alloxanthine DHPP
n6:IUPAC-Name
n12:271B3F5D-363D-11E5-9242-09173F13E4C5
n6:InChI
n12:271B3F63-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n12:271B3F62-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n12:271B3F5F-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n12:271B3F60-363D-11E5-9242-09173F13E4C5
n6:SMILES
n12:271B3F61-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n12:271B3F5B-363D-11E5-9242-09173F13E4C5
n6:logP
n12:271B3F59-363D-11E5-9242-09173F13E4C5 n12:271B3F5C-363D-11E5-9242-09173F13E4C5
n6:logS
n12:271B3F5A-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Acceptor-Count
n12:271B3F69-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n12:271B3F6A-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n12:271B3F64-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n12:271B3F65-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n12:271B3F67-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n12:271B3F66-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n12:271B3F68-363D-11E5-9242-09173F13E4C5
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
2465-59-0
n6:category
n6:Bioavailability
n12:271B3F6F-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n12:271B3F71-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n12:271B3F72-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n12:271B3F6E-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n12:271B3F6D-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n12:271B3F70-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n12:271B3F5E-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n12:271B3F6B-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n12:271B3F6C-363D-11E5-9242-09173F13E4C5